Caris Life Sciences (NASDAQ:CAI) Shares Gap Down – Here’s What Happened

Shares of Caris Life Sciences, Inc. (NASDAQ:CAI) gapped down prior to trading on Thursday. The stock had previously closed at $33.22, but opened at $27.18. Caris Life Sciences shares last traded at $26.7540, with a volume of 1,211,277 shares traded.

Caris Life Sciences News Summary

Here are the key news stories impacting Caris Life Sciences this week:

• Positive Sentiment: Citigroup raised its price target to $36 from $28 and maintained a Buy rating. BTIG Research also reiterated Buy, with a $38 target. Citigroup rating BTIG rating
• Positive Sentiment: Goldman Sachs stuck with its Buy rating, adding to the favorable analyst sentiment around CAI. Goldman Sachs rating
• Positive Sentiment: Third-quarter revenue grew 27% year over year to $275.36 million, while EPS of $0.05 beat the $0.03 consensus. Caris also raised its fiscal 2026 outlook, supporting expectations for continued growth. Q3 results and outlook
• Negative Sentiment: Despite the revenue growth and EPS beat, net income declined 37% year over year, with higher expenses weighing on profitability. EPS was also below the $0.08 reported a year earlier, a potential concern for investors focused on margins. Profit decline report

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on CAI. TD Cowen increased their target price on shares of Caris Life Sciences from $36.00 to $38.00 and gave the company a “buy” rating in a research note on Thursday. Weiss Ratings cut Caris Life Sciences from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, October 2nd. Wall Street Zen upgraded Caris Life Sciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 16th. Citigroup lifted their target price on Caris Life Sciences from $28.00 to $36.00 and gave the stock a “buy” rating in a research report on Friday. Finally, JPMorgan Chase & Co. boosted their target price on shares of Caris Life Sciences from $25.00 to $35.00 and gave the company an “overweight” rating in a research note on Wednesday, October 14th. Eight equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.82.

Caris Life Sciences Stock Down 3.1%

The business has a 50 day moving average of $29.48 and a two-hundred day moving average of $21.74. The stock has a market capitalization of $7.13 billion, a PE ratio of 76.45 and a beta of 0.71. The company has a debt-to-equity ratio of 0.66, a quick ratio of 4.88 and a current ratio of 5.53.

Caris Life Sciences (NASDAQ:CAI) last released its earnings results on Wednesday, November 4th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.03 by $0.02. The company had revenue of $275.36 million during the quarter. Caris Life Sciences had a net margin of 10.62% and a return on equity of 18.77%. The firm’s revenue for the quarter was up 27.0% on a year-over-year basis. During the same quarter last year, the business earned $0.08 earnings per share. Analysts predict that Caris Life Sciences, Inc. will post 0.13 EPS for the current year.

Insider Activity

In other news, President David Spetzler sold 478,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $24.86, for a total transaction of $11,883,080.00. Following the completion of the sale, the president owned 1,052,083 shares in the company, valued at $26,154,783.38. This trade represents a 31.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Russel Denton sold 7,500 shares of the stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $31.82, for a total value of $238,650.00. Following the transaction, the insider owned 174,855 shares of the company’s stock, valued at approximately $5,563,886.10. This represents a 4.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 1,004,712 shares of company stock worth $27,205,419 over the last quarter. 50.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CAI. Renaissance Technologies LLC lifted its position in shares of Caris Life Sciences by 36.4% during the 1st quarter. Renaissance Technologies LLC now owns 449,900 shares of the company’s stock worth $8,044,000 after purchasing an additional 120,000 shares during the last quarter. Maxi Investments CY Ltd acquired a new position in shares of Caris Life Sciences in the 2nd quarter valued at $3,754,000. Moore Capital Management LP acquired a new position in Caris Life Sciences in the second quarter valued at $1,139,000. Sei Investments Co. grew its stake in Caris Life Sciences by 2,348.6% during the 1st quarter. Sei Investments Co. now owns 598,712 shares of the company’s stock worth $10,705,000 after buying an additional 574,261 shares during the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new position in Caris Life Sciences during the second quarter worth approximately $848,000.

About Caris Life Sciences

Caris Life Sciences is a biotechnology and precision-medicine company that uses molecular profiling and artificial intelligence to support cancer diagnosis, treatment selection and drug development. The company analyzes tumor and blood samples to identify genomic, molecular and immune characteristics that may help physicians better understand a patient’s disease and select targeted therapies.

Its offerings include comprehensive tumor profiling, liquid-biopsy testing and data-driven clinical decision-support tools.